Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average recommendation of “Buy” from the fourteen ratings firms that are currently covering the stock. Two analysts have rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $15.81.

Several equities research analysts recently weighed in on KPTI shares. S&P Equity Research decreased their price objective on Karyopharm Therapeutics from $9.06 to $7.55 in a report on Tuesday, August 30th. Vetr lowered Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 price objective for the company. in a report on Wednesday, August 31st. Canaccord Genuity set a $20.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Saturday, August 6th. Jefferies Group raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $9.00 to $12.00 in a report on Tuesday, August 30th. Finally, HC Wainwright started coverage on Karyopharm Therapeutics in a report on Thursday, August 18th. They issued a “buy” rating and a $15.00 price objective for the company.

Karyopharm Therapeutics (NASDAQ:KPTI) opened at 8.61 on Wednesday. Karyopharm Therapeutics has a 1-year low of $4.83 and a 1-year high of $19.41. The stock has a 50 day moving average price of $9.32 and a 200 day moving average price of $8.43. The firm’s market cap is $309.87 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.08. On average, analysts anticipate that Karyopharm Therapeutics will post ($3.22) EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $136,000. Nationwide Fund Advisors increased its stake in shares of Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock worth $143,000 after buying an additional 5,886 shares during the period. ProShare Advisors LLC increased its stake in shares of Karyopharm Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 29,655 shares of the company’s stock worth $199,000 after buying an additional 376 shares during the period. Highbridge Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $200,000. Finally, Alliancebernstein L.P. increased its stake in shares of Karyopharm Therapeutics by 24.2% in the second quarter. Alliancebernstein L.P. now owns 34,930 shares of the company’s stock worth $234,000 after buying an additional 6,800 shares during the period. Hedge funds and other institutional investors own 55.71% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.